Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
13.8
％（親会社所有者帰属当期利益の予想修正率）Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending December 2025 · Full yearNet Sales32,750→34,560hundred million
+5.5%
Operating profit7,510→8,450hundred million
+12.5%
Profit attributable to owners of the parent4,940→5,620hundred million
+13.8%
Net income per share—→316.55yen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
足元までの状況等を織り込んだことに伴うもの。医薬事業を非継続事業に分類し、前回予想も同様に組み替えて比較している。
Details and amount of extraordinary loss
減損損失27,069百万円。カナダ訴訟損失引当金は、供託額約179,952百万円と同額を取り崩し。
Dividend forecast revision修正あり。2025年12月期の期末配当予想は130.00円、年間配当予想は234.00円。増減方向はNot disclosed。
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | ¥32,750 hundred million → ¥34,560 hundred million（+5.5%） |
| Operating profit | ¥7,510 hundred million → ¥8,450 hundred million（+12.5%） |
| Profit attributable to owners of the parent | ¥4,940 hundred million → ¥5,620 hundred million（+13.8%） |
| Net income per share | Not disclosed → 316.55 yen |
| Fiscal Period Covered | Fiscal year ending December 2025 |
| Period Covered | Full year |
| Reason for the revision | 足元までの状況等を織り込んだことに伴うもの。医薬事業を非継続事業に分類し、前回予想も同様に組み替えて比較している。 |
| Details and amount of extraordinary loss | 減損損失27,069百万円。カナダ訴訟損失引当金は、供託額約179,952百万円と同額を取り崩し。 |
| Dividend forecast revision | 修正あり。2025年12月期の期末配当予想は130.00円、年間配当予想は234.00円。増減方向はNot disclosed。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
Ordinary incomePublication date of previous forecastPrevious-period results
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.足元までの状況等を織り込んだことに伴うもの。医薬事業を非継続事業に分類したため、業績予想と前回予想を継続事業ベースに組み替えて比較している。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.